LITS
Lite Strategy, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.14
+9.62%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 65.3M | 48.8M | 40.7M |
| Cost of Revenue | — | 368.0K | — | — | — |
| Gross Profit | — | (368.0K) | 65.3M | 48.8M | 40.7M |
| Operating Expenses | |||||
| R&D Expense | 169.0K | 3.9M | 16.6M | 52.5M | 85.6M |
| SG&A Expense | 11.9M | 13.5M | 23.3M | 33.1M | 30.5M |
| General & Admin Expense | 9.2M | 13.5M | 23.3M | 33.1M | 30.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 631.0K | (368.0K) | 10.9M | — | — |
| Total Operating Expenses | 12.7M | 17.1M | 50.8M | 85.6M | 116.2M |
| Cost and Expenses | 12.7M | 17.5M | 50.8M | 85.6M | 116.2M |
| Operating Income (EBIT) | (12.7M) | (17.5M) | 14.5M | (36.8M) | (75.5M) |
| Non-Operating | |||||
| Interest Income | 404.0K | 1.0M | 3.3M | 3.3M | 284.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 404.0K | 1.0M | 3.3M | 3.3M | 284.0K |
| Other Non-Op Income/Expense | (48.1M) | 1.5M | 3.2M | 4.9M | 21.0M |
| Non-Operating Income (excl Interest) | (631.0K) | — | (10.9M) | — | — |
| EBT (Pre-Tax Income) | (60.8M) | (15.9M) | 17.8M | (31.8M) | (54.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (60.8M) | (15.9M) | 17.8M | (31.8M) | (54.5M) |
| Earnings from Cont. Ops | (60.8M) | (15.9M) | 17.8M | (31.8M) | (54.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (60.8M) | (15.9M) | 17.8M | (31.8M) | (62.5M) |
| Per Share | |||||
| Basic EPS | ($9.13) | ($2.39) | $2.67 | ($4.78) | ($10.04) |
| Diluted EPS | ($9.13) | ($2.39) | $2.67 | ($4.78) | ($9.99) |
| Revenue Per Share | $0.00 | $0.00 | $9.80 | $7.33 | $6.54 |
| Shares | |||||
| Basic Shares Outstanding | 6.7M | 6.7M | 6.7M | 6.7M | 6.2M |
| Diluted Shares Outstanding | 6.7M | 6.7M | 6.7M | 6.7M | 6.3M |
| Profitability Metrics | |||||
| EBITDA | (12.1M) | (17.1M) | 25.8M | (36.4M) | (75.2M) |
| D&A | — | 368.0K | 383.0K | 386.0K | 326.0K |
| EBIT | (12.1M) | (17.5M) | 25.4M | (36.8M) | (75.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026